• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Applied BioMath, Syntimmune collaborate onautoimmune diseases

Applied BioMath, Syntimmune collaborate onautoimmune diseases

December 4, 2017
CenterWatch Staff

Applied BioMath, a provider in applying mechanistic modeling to drug research and development, announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune's ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune's lead drug candidate, SYNT001. The goal is to create a semi-mechanistic PK/PD model to support further advancement of Syntimmune's clinical trials of SYNT001 in a broad variety of IgG-mediated autoimmune diseases, including ongoing trials in Warm Autoimmune Hemolytic Anemia, Pemphigus, and other clinical indications.

"Our collaboration with Applied BioMath will allow us to gain additional validation of SYNT001's differentiated properties, particularly in regard to the dose level, dosing frequency, and planned subcutaneous administration of our promising lead compound. We anticipate this collaboration will allow us to best optimize FcRn inhibition in the context of therapeutic induction and maintenance, enabled by our deep understanding of the underlying biology," said David de Graaf, Ph.D., CEO of Syntimmune. "Applied BioMath has a stellar track record in helping customers with similar objectives, and we look forward to leveraging their capabilities for our program."

Applied BioMath's MADI approach involves rigorous fit-for-purpose model development and optimization techniques to estimate model parameters and variability using proprietary algorithms and software. Top pharmaceutical and biotechnology companies leverage Applied BioMath's MADI approach to accelerate their candidates to market and to de-risk their research and development (R&D) from early research through to clinical trials. "We look forward to supporting Syntimmune as they progress further into the clinic," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "This is a critical stage in R&D where strategic questions benefit greatly from the support of MADI."

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing